Pharma

Ono forms partnership with Jorna on RNA Editing Drug Research

Ono Pharmaceutical Co., Ltd. announced that it has entered into a research collaboration agreement with Jorna Therapeutics in December 2024 aimed at drug discovery using Jorna's proprietary ribonucleic acid (RNA) editing platform. Having completed the validation of this platform, Ono has begun the search for nucleic acid sequences that could serve as drug candidates. Under the agreement, Jorna will design RNA editing drug sequences using its proprietary protein and RNA generative AI model, which is based on the quantum mechanics-based AI called SkyEngine. Ono will have an exclusive option right to discover, develop, and commercialize drug candidates generated by the sequences designed by Jorna worldwide. In addition to the upfront payment already made to Jorna, Ono will also pay for research funding and milestone payments based on the progress of…